These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1011 related articles for article (PubMed ID: 33482121)
1. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Gay CM; Stewart CA; Park EM; Diao L; Groves SM; Heeke S; Nabet BY; Fujimoto J; Solis LM; Lu W; Xi Y; Cardnell RJ; Wang Q; Fabbri G; Cargill KR; Vokes NI; Ramkumar K; Zhang B; Della Corte CM; Robson P; Swisher SG; Roth JA; Glisson BS; Shames DS; Wistuba II; Wang J; Quaranta V; Minna J; Heymach JV; Byers LA Cancer Cell; 2021 Mar; 39(3):346-360.e7. PubMed ID: 33482121 [TBL] [Abstract][Full Text] [Related]
2. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975 [TBL] [Abstract][Full Text] [Related]
4. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040 [TBL] [Abstract][Full Text] [Related]
5. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388 [TBL] [Abstract][Full Text] [Related]
6. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma. Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667 [TBL] [Abstract][Full Text] [Related]
7. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680 [TBL] [Abstract][Full Text] [Related]
8. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573 [TBL] [Abstract][Full Text] [Related]
9. Molecular features and evolutionary trajectory of ASCL1 Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551 [TBL] [Abstract][Full Text] [Related]
10. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor. Kim G; Kim M; Nam EJ; Lee JY; Park E Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745 [TBL] [Abstract][Full Text] [Related]
12. Killing SCLC: insights into how to target a shapeshifting tumor. Sutherland KD; Ireland AS; Oliver TG Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269 [TBL] [Abstract][Full Text] [Related]
13. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. Peressini M; Garcia-Campelo R; Massuti B; Martí C; Cobo M; Gutiérrez V; Dómine M; Fuentes J; Majem M; de Castro J; Córdoba JF; Diz MP; Isla D; Esteban E; Carcereny E; Vila L; Moreno-Vega A; Ros S; Moreno A; García FJ; Huidobro G; Aguado C; Cebey-López V; Valdivia J; Palmero R; Lianes P; López-Brea M; Vidal OJ; Provencio M; Arriola E; Baena J; Herrera M; Bote H; Molero M; Adradas V; Ponce-Aix S; Nuñez-Buiza A; Ucero Á; Hernandez S; Lopez-Rios F; Conde E; Paz-Ares L; Zugazagoitia J Clin Cancer Res; 2024 Jul; 30(14):3036-3049. PubMed ID: 38630755 [TBL] [Abstract][Full Text] [Related]
14. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer. Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534 [TBL] [Abstract][Full Text] [Related]
16. Small cell lung cancer: Subtypes and therapeutic implications. Wang WZ; Shulman A; Amann JM; Carbone DP; Tsichlis PN Semin Cancer Biol; 2022 Nov; 86(Pt 2):543-554. PubMed ID: 35398266 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer. Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600 [TBL] [Abstract][Full Text] [Related]
18. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Redin E; Sridhar H; Zhan YA; Pereira Mello B; Zhong H; Durani V; Sabet A; Manoj P; Linkov I; Qiu J; Koche RP; de Stanchina E; Astorkia M; Betel D; Quintanal-Villalonga Á; Rudin CM J Hematol Oncol; 2024 Jul; 17(1):58. PubMed ID: 39080761 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity. Qi J; Zhang J; Liu N; Zhao L; Xu B Front Oncol; 2022; 12():779276. PubMed ID: 35311069 [TBL] [Abstract][Full Text] [Related]